RHÖN-KLINIKUM AG reports results for the third quarter of 2026

RHÖN-KLINIKUM Aktiengesellschaft

/ Key word(s): 9 Month figures/Quarter Results

RHÖN-KLINIKUM AG reports results for the third quarter of 2026

05.11.2026 / 09:02 CET/CEST

The issuer is solely responsible for the content of this announcement.


CORPORATE NEWS

RHÖN-KLINIKUM AG reports results for the third quarter of 2026

  • Group makes targeted investments in state-of-the-art medical technology
  • Number of patients treated up 8.3%, with revenues increasing to
    EUR 1,304 million
  • Increase in the operating result is driven by a 3.25% surcharge on hospital services, which is accounted for in 2026
  • Strong capital base with high equity ratio provides solid foundation for optimising inpatient and outpatient care structures

 

Bad Neustadt, 5 November 2026 – RHÖN-KLINIKUM AG closed the first nine months of 2026 with strong earnings growth. Despite healthcare policy challenges and a difficult economic environment, the number of patients was increased and consolidated profit was improved.

From January to September 2026 a total of 764,248 patients were treated on an inpatient and outpatient basis in the Group’s hospitals and medical care centres, an increase of 8.3% (9M 2025: 705,830). Consolidated revenue of EUR 1,303.8 million exceeded the previous year’s level (9M 2025: EUR 1,262.1 million), and EBITDA was EUR 83.9 million (9M 2025: EUR 71.8 million). The result is impacted by a billing surcharge (3.25% on hospital services) that is accounted for and reported under “other income” through October 2026. It is intended to offset the increases in personnel and non-personnel costs experienced in previous years. Consolidated profit increased to EUR 32.7 million (9M 2025: EUR 25.1 million).

The increase is primarily the result of higher capacity utilization at clinics and medical care centers, as well as an increase in patient numbers, particularly in the outpatient sector. The company’s strong capital base with an equity ratio of 74.7% moreover provides a solid foundation for optimising inpatient and outpatient care structures.

Dr. Gunther K. Weiß, member of the Board of Management of RHÖN-KLINIKUM AG: “Our successful third quarter shows that financial stability and medical excellence are inseparable, going hand in hand. Underlying this success is the tremendous trust out patients put in us. This sustainable basis is what allows us to continue making targeted investments in state-of-the-art medical technology and care offerings.”

This course of innovation is evident in two selected investments: at Universitätsklinikum Marburg, a state-of-the-art photon-counting computer tomograph was put into service. That makes RHÖN-KLINIKUM AG the only hospital group in Germany having four newest-generation units of this kind in operation. With the new hybrid operating theatre in Frankfurt (Oder), the hospital has expanded its treatment range, thus strengthening its interdisciplinary structures and giving a further major boost to the maximum care facility’s care offerings in the Ostbrandenburg region.

Dr. Stefan Stranz, member of the Board of Management of RHÖN-KLINIKUM AG: “This forward-looking investment strategy ensures that we can continue to operate effectively in a market environment facing far-reaching and sweeping change. Thanks to our solid financial basis and our collaboration within the ASKLEPIOS Group network, we can take on and actively shape this transformation process from a position of strength.”

Outlook for 2026

For the current financial year, we expect revenues of EUR 1.7 billion within a range of plus or minus 5%. For earnings before interest, tax and depreciation/ amortisation (EBITDA), we expect a level of between EUR 110 million and EUR 125 million. In addition to financial performance indicators, we also take account of the non-financial performance indicators of number of cases and cost weights in the management of the company and expect these to show a moderate improvement over the previous year.

The financial year will be significantly impacted by the unfolding legislation process and the considerable uncertainties it holds. Particularly the Hospital Reform Adjustment Act (Krankenhausreformanpassungsgesetz, KHAG) that entered into force on 15 April 2026 and the Statutory Health Insurance (SHI) Contribution Rate Stabilisation Act (GKV-Beitragsstabilisierungsgesetz, GKV-BstabG) (GKV-BStabG) adopted by the German Federal Parliament on 10 July 2026 seek to further enhance quality and efficiency in the healthcare system, but at the same time will put hospitals under greater financial pressure in the short term.

The company’s forecast is therefore subject to particular uncertainties. It is not yet possible at this time to reliably forecast what overall impact the ongoing regulatory interference, implementation of the hospital reform as well as further possible adjustments by the legislator will have. On top of that, ongoing global crises and negative economic impacts are resulting among other things in higher prices, supply bottlenecks and general market volatility.

The Quarterly Statement for Q3 2026 is published on the Internet.

CONTACT

RHÖN-KLINIKUM AG | Head of Group Finance
Norman Dittes | T. +49 9771 65-12210 | norman.dittes@rhoen-klinikum-ag.com

RHÖN-KLINIKUM AG | Corporate Communications
Heike Ochmann | T. +49 9771 65-12130 | heike.ochmann@rhoen-klinikum-ag.com

RHÖN-KLINIKUM AG | Schlossplatz 1 | D-97616 Bad Neustadt a. d. Saale

 

RHÖN-KLINIKUM AG is one of the largest healthcare providers in Germany, with five highly specialised maximum- and intermediate-care facilities: Campus Bad Neustadt, Zentralklinik Bad Berka, Klinikum Frankfurt (Oder) as well as the Giessen and Marburg University Hospitals (UKGM). As a modern, diverse and future-oriented Company, RHÖN-KLINIKUM AG is attractive both as a provider of training and an employer. With over 19,100 employees, the Group offers excellent medical care with a direct tie-in to research and teaching. Each year, we treat a total of 938,000 patients at our hospitals and medical care centres (MVZs) on an outpatient and inpatient basis. Die RHÖN-KLINIKUM AG is a company of the ASKLEPIOS Group. www.rhoen-klinikum-ag.com


05.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: RHÖN-KLINIKUM Aktiengesellschaft
Salzburger Leite 1
97616 Bad Neustadt a. d. Saale
Germany
Phone: +49 (0)9771 – 65-0
Fax: +49 (0)9771 – 97 467
E-mail: rka@rhoen-klinikum-ag.com
Internet: www.rhoen-klinikum-ag.com
ISIN: DE0007042301
WKN: 704230
Listed: Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate BSX
LEI Code: 529900MVGMIVUDQY9E20
EQS News ID: 2428858

 
End of News EQS News Service

2428858  05.11.2026 CET/CEST

Phillips Medisize Acquires Chippenham Facility to Expand Global Inhalation Center of Excellence

Phillips Medisize Acquires Chippenham Facility to Expand Global Inhalation Center of Excellence




Phillips Medisize Acquires Chippenham Facility to Expand Global Inhalation Center of Excellence

  • The investment strengthens the company’s Global Inhalation Center of Excellence that also includes a dedicated facility in Cambridge.
  • Building on the 2025 acquisition of Vectura Group Ltd., which added critical inhalation capabilities to the company’s existing suite of drug delivery devices, this Chippenham expansion enables Phillips Medisize to leverage its global footprint to accelerate innovation and significantly grow its inhalation revenue.
  • Pharmaceutical customers addressing complex conditions such as Pulmonary Arterial Hypertension (PAH), along with non-respiratory diseases affecting millions worldwide, rely on the company’s extensive inhalation combination product development expertise and its ability to scale device manufacturing globally.

CHIPPENHAM, England & HUDSON, Wis.–(BUSINESS WIRE)–#Biologics—Phillips Medisize, a Molex company and a leader in the design, development, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, today announced an investment to acquire the complete footprint of its Chippenham site. Together with its Cambridge location, the newly acquired facility strengthens the company’s Global Inhalation Center of Excellence (COE) and provides additional capacity to support projected business growth.


Following the acquisition of Vectura Group Ltd., the combined capabilities are driving growth as expanded inhalation expertise and Phillips Medisize’s global footprint create new opportunities to innovate, scale and serve customers. The Chippenham footprint of 58,963 square meters (about 634,670 square feet) on approximately 3.41 acres provides Phillips Medisize with long-term operational control to broaden drug-device combination product formulation development for both early and late-phase clinical trial supplies manufacturing. This acquisition supports an anticipated growing pipeline of complex inhaled small molecule and biologic therapies. Industry data from AlphaSense indicates the market for inhalation and nasal drug delivery devices is experiencing robust growth. This expansion is driven by broadening respiratory drug pipelines and a structural shift toward outsourcing the development of complex combination products.

“With our inhalation revenue projected to grow substantially over the next five years, securing this full site ensures we have the dedicated talent, laboratories and cleanroom capacity required to support pharmaceutical companies from early-stage feasibility all the way through commercial scale-up,” said Charlie Schumacher, vice president of inhalation therapies at Phillips Medisize. “Since the Vectura acquisition, we are tracking ahead of schedule on our growth model and are confident in our trajectory. This expansion in Chippenham reinforces our momentum and ensures proven technical expertise and manufacturing continuity for our customers worldwide.”

The combined Chippenham and Cambridge locations serve as the company’s dedicated Global Inhalation COE. Across both facilities, Phillips Medisize provides end-to-end combination product development and manufacturing capabilities for small molecules, biologics and generic products.

“We are deeply grateful for the overwhelming support and positive reception we continue to receive from our customers and the broader respiratory industry following the Vectura acquisition,” said Sandy Munro, chief inhalation scientist at Phillips Medisize. “Our team is absolutely delighted to be where we should be, back at industry conferences and on the podium sharing our latest research. We remain deeply committed to advancing the science in our field to bring more effective inhalation therapies to patients across the world, including those dealing with complex and challenging diseases like Pulmonary Arterial Hypertension (PAH).”

The Global Inhalation COE supports all major inhalation formats, including dry powder inhalers (DPIs) and nebulizers. These device platforms are backed by comprehensive pharmaceutical development services encompassing powder and liquid formulation expertise. This includes advanced particle engineering via spray drying and powder blending at a broad range of scale, alongside full analytical testing, technical transfer and clinical trial supply manufacturing.

Beyond the inhalation COE, Phillips Medisize offers customers a fully integrated global network featuring 30 locations across North America, Europe and Asia, with 23 production facilities and seven R&D innovation centers. Having supported more than 200 product launches and 150 drug delivery programs over the past five years, Phillips Medisize provides the proven capability required to bring complex therapies from development to commercialization.

About Phillips Medisize

Phillips Medisize, a Molex company, collaborates with leading pharmaceutical, medical technology and in vitro diagnostic companies to design, engineer and manufacture lifesaving innovations. A contract development and manufacturing organization (CDMO), Phillips Medisize leverages its 60 years of expertise and globally renowned capabilities to collaborate with customers to deliver products and solutions that annually help millions of patients, healthcare professionals and individuals live healthier, more productive lives. For more information, visit www.phillipsmedisize.com.

About Molex

Molex is a global electronics leader committed to making the world a better, more-connected place. With a presence in more than 40 countries, Molex enables transformative technology innovation in the consumer device, aerospace and defense, data center, cloud, telecommunications, transportation, industrial automation and healthcare industries. Through trusted customer and industry relationships, unrivaled engineering expertise and product quality and reliability, Molex realizes the infinite potential of Creating Connections for Life. For more information, visit www.molex.com.

Contacts

Media Contact:
M+

Healthcare Marketing & Communications

Paula Moggio

Paula@mplushealth.com

Amphista Therapeutics to Present AMX-883 Data at American Society of Hematology (ASH) Annual Meeting

Amphista Therapeutics to Present AMX-883 Data at American Society of Hematology (ASH) Annual Meeting




Amphista Therapeutics to Present AMX-883 Data at American Society of Hematology (ASH) Annual Meeting

  • AMX-883-mediated BRD9 degradation disrupts hematopoietic transcriptional programs, promotes myeloid differentiation, and depletes leukemic stem cells in acute myeloid leukemia (AML)
  • Additional abstract on AMX-883 BRAMLIE trial assessing safety, pharmacokinetics, and preliminary efficiency to publish in Blood

CAMBRIDGE, England–(BUSINESS WIRE)–Amphista Therapeutics Limited (‘Amphista’ or ‘the Company’), a clinical-stage biopharmaceutical company focused on the discovery and development of non-cereblon / VHL targeted protein degradation (TPD) medicines, today announced new data on its lead therapeutic candidate, AMX-883, has been accepted for oral presentation at American Society of Hematology (ASH) Annual Meeting in New Orleans, December 12–15, 2026. The full abstract is available online: www.hematology.org/Meetings/Annual-Meeting/Abstracts


The data, to be presented by Dr Louise Modis, CEO, suggest BRD9 plays a critical role in acute myeloid leukemia (AML), maintaining activity of a number of hematopoietic transcription factors. Degradation of BRD9 using AMX-883 restricts these transcription factor programs, releasing the differentiation block and reducing the frequency of leukemic stem cells.

Presentation details:

  • Title: AMX-883-mediated BRD9 degradation disrupts hematopoietic transcriptional programs, promotes myeloid differentiation, and depletes leukemic stem cells in acute myeloid leukemia
  • Session: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Cell-Intrinsic and Niche-Mediated Mechanisms of Drug Resistance in AML. December 14, 2026, 10:30 AM – 12:00 PM
  • Room: MCCNO – Great Hall BC
  • Presentation time: December 14, 2026, 11:45 AM – 12:00 PM
  • Publication number: 762
  • Submission ID: abs26-9908

The second abstract, due to be published in the ASH Blood Supplement, highlights Amphista’s ongoing AMX-883 BRAMLIE trial (1), an open label, multi-part, dose escalation and optimization study:

  • Abstract number: abs26-2088
  • Title: A Phase 1, open-label, multi-centre study to assess the safety, pharmacokinetics, and preliminary efficacy of AMX-883 monotherapy in participants with acute myeloid leukemia and high-risk myelodysplastic syndrome and in combination in participants with AML
  • Category: 600s – Hematologic Malignancy
  • Review category: 616. Acute Myeloid Leukemias: lnvestigational Drug and Cellular Therapies
  • Authors: Eytan Stein, Emma Searle, Amir Fathi, Jayastu Senapati, Justin Watts, Victoria Campbell, Jenny O’Nions, Alexander Spira, David Taussig, Paul Player, Giulia Petrone, Anthony Selwyn Stein, Lisa Butler, Patrick Kelly
  1. https://amphista.com/amphista-therapeutics-announces-first-patient-dosed-in-amx-883-phase-1-clinical-trial-for-acute-myeloid-leukemia/

Contacts

Media contact:
Lorna Cuddon

Zyme Communications

Tel: +44(0)7811 996 942

Email: lorna.cuddon@zymecommunications.com

Evotec Reports Third Quarter and Nine-Month 2026 Results: Building Growth Momentum Toward 2030 Goals

Evotec SE

/ Key word(s): 9 Month figures/Quarterly / Interim Statement

Evotec Reports Third Quarter and Nine-Month 2026 Results: Building Growth Momentum Toward 2030 Goals

05.11.2026 / 07:30 CET/CEST

The issuer is solely responsible for the content of this announcement.


Evotec Reports Third Quarter and Nine-Month 2026 Results: Building Growth Momentum Toward 2030 Goals
 

  • Financial performance: Q3 and nine-month Group revenue of €164.9 m and €465.0 m, respectively (Q3: €164.2 m, 9M: €477.4 m at CER); adj. Group EBITDA of -€1.6 m and -€44.3 m, respectively (Q3: -€1.7 m, 9M: -€39.1 m at CER)
  • Robust commercial momentum: Net sales* in D&PD base business increased 24% vs. 9M 2025 accompanied by continued positive development across key commercial indicators.
  • FY 2026 guidance reaffirmed: Expected Group revenue of €570 to €610 m (€595 to €635 m CER) and adj. Group EBITDA of -€105 to -€70 m (-€90 to -€60 m CER).
  • 2030 framework further detailed: Around €1 billion in Group revenue by 2030 with further upside potential; adjusted EBITDA margin of 20% at YE 2028 and above 20% at YE 2030.
  • Continued progress across differentiated platforms: Evotec confirms selection by Vertex Pharmaceuticals for commercial manufacturing of povetacicept; advancement of orthopoxvirus antibody program into Phase 1 in collaboration with DoW; new collaborations with Plectonic and Odyssey Therapeutics broaden partnered innovation activities.
  • Horizon transformation ahead of plan: More than 20% of €75 million annual run-rate savings target delivered by September, already within 20-30% contribution planned for full-year 2026; workforce and footprint measures on track.
  • Leadership Update: Dr. Joanna Holbrook appointed Chief Scientific Officer, strengthening Evotec’s focus on scientific excellence, platform differentiation and partnered innovation.
  • Investor and analyst webcast and conference call today: 2 p.m. CET / 1 p.m. GMT / 8 a.m. EST; registration and webcast details below.

Hamburg, Germany, November 5, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced financial results for the third quarter and first nine months of 2026, provided an update on the implementation of its Horizon transformation and outlined its strategic and financial ambition for 2030.

Dr. Christian Wojczewski, Chief Executive Officer of Evotec, said:

“During the third quarter and first nine months of 2026, we made encouraging progress across several areas that are important to Evotec’s future development. Commercial momentum remained solid, Horizon is delivering ahead of plan and Just – Evotec Biologics is advancing toward commercial-scale manufacturing. Implementation of our strategy is gaining momentum and is increasingly reflected in our performance. Group revenue reached €164.9 million in the third quarter, well above the first two quarters of the year, supported by a robust contribution from the D&PD base business.

We also successfully launched several new partnerships based on our technology platforms. Recent examples include Plectonic, where we are exploring new T-cell-engaging approaches in solid tumors. With Odyssey Therapeutics, our AI-enabled discovery platform is supporting drug discovery in autoimmune and inflammatory diseases. These collaborations illustrate how we are applying our differentiated scientific capabilities in new areas, creating exciting opportunities with partners.”

Selected Business Highlights

Evotec made strong progress across its differentiated platforms and strategic partnerships:

Just – Evotec Biologics (JEB)

  • Vertex Pharmaceuticals – Commercial Manufacturing of Povetacicept: Evotec confirms that Just – Evotec Biologics has been selected by Vertex Pharmaceuticals for commercial manufacturing of povetacicept at its J.POD® Redmond facility. The agreement marks an important step in the evolution of JEB’s continuous manufacturing platform toward commercial readiness. Evotec is highly confident in its ability to fulfill its commercial manufacturing and supply commitments to Vertex.
  • DoW Orthopoxvirus Program – JST-018 Phase 1 Initiated: In September 2026, Evotec announced the initiation of a Phase 1 clinical trial evaluating JST-018, an investigational antibody cocktail developed by Just – Evotec Biologics under the U.S. Department of War’s Accelerated Antibodies Program. Just – Evotec Biologics advanced the program from antibody sequence selection through preclinical development, process development, regulatory submission and cGMP manufacture of clinical trial materials.

Discovery and Preclinical Development (D&PD)

  • Jazz Pharmaceuticals – Phase 1 Initiated: Jazz Pharmaceuticals has initiated a Phase 1 clinical trial of a candidate for the potential treatment of narcolepsy and idiopathic hypersomnia. The candidate was discovered through Jazz’s sleep disorders collaboration with Evotec. Evotec combined its proprietary virtual screening and generative AI platforms with rational design to identify novel leads, subsequently optimized with the aid of cryoEM and molecular dynamics simulations. Evotec is eligible to milestone payments.
  • Plectonic Research Collaboration – Novel Immunotherapy Approaches: In September 2026, Evotec and Plectonic entered a research collaboration combining Evotec’s BiTco platform with Plectonic’s LOGIBODY® technology to explore new T-cell-engaging approaches for solid tumors. The collaboration will generate preclinical proof-of-concept data to evaluate whether the combined technologies can improve the precision and potency of these approaches.
  • Odyssey Therapeutics Research Collaboration – AI-Enabled Drug Discovery: In August 2026, Evotec entered an R&D collaboration combining Odyssey’s expertise in autoimmune and inflammatory diseases with Evotec’s AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries. Evotec is eligible to receive milestone payments based on the successful delivery of validated starting points for drug discovery across multiple targets.

Commercial Execution

Commercial momentum and execution continued to strengthen during the third quarter of 2026. Net sales in the D&PD base business, comprising stand alone services and integrated programs, increased by 24% year-on-year in the first nine months. Positive trends extended across the commercial funnel, with growth in the customer base, higher proposal activity and faster proposal turnaround. The strategic partnership opportunity pipeline also continued to expand.

Horizon Transformation

Horizon is progressing ahead of plan, with structural measures translating into measurable financial and operational improvements. By the end of September, Evotec had delivered more than 20% of the €75 million in annual run-rate savings targeted by the end of 2027, already within the 20-30% contribution planned for full-year 2026. Approximately half of the planned workforce reductions have been implemented. Footprint consolidation is advancing, with three of the four site closures expected to be completed by year-end and the fourth in the first quarter of 2027. Alongside these measures, Evotec is concentrating scientific capabilities in focused Centers of Excellence and strengthening commercial execution to build a more efficient operating model and support sustainable profitability. Evotec expects to deliver the transformation program in full and on schedule by the end of 2027.

Leadership Update

Chief Scientific Officer: Dr. Joanna Holbrook

As announced on October 15, 2026, Dr. Joanna Holbrook has succeeded Dr. Cord Dohrmann as Chief Scientific Officer and member of Evotec’s Management Board, effective November 1, 2026.

Bringing more than 25 years of experience as a scientist and R&D leader, Dr. Holbrook will lead Evotec’s global scientific strategy, with a focus on strengthening scientific differentiation across discovery and development services, technology platforms and proprietary innovation. Her expertise across data, AI and novel technologies will support Evotec in building integrated solutions to important challenges in drug discovery and helping customers and partners discover and develop new medicines faster and with a greater probability of success.

2030 Mid-Range Framework – Building a Structurally Stronger Business

Evotec is building a more balanced and profitable business, drawing on the distinctive strengths of its component parts. The 2030 framework calls for around €1 billion in Group revenue by 2030, with potential for additional upside. It includes an adjusted EBITDA margin of 20% by the end of 2028, rising above 20% by the end of 2030.

The D&PD base business, comprising standalone services and integrated programs, is expected to contribute approximately 40% of Group revenue in 2030. Growth is expected to be supported by continued market recovery, commercial investments and Evotec’s differentiated service offerings.

D&PD strategic partnerships and innovation-related activities are expected to contribute approximately 20% at above-average margins. This contribution incorporates risk-adjusted assumptions regarding program progression and associated revenue, while future royalty income is not included. Performance exceeding these assumptions could provide additional revenue upside beyond the approximately €1 billion framework.

Just – Evotec Biologics is expected to contribute approximately 40% of Group revenue as the business scales, supported by capacity expansion, licensing income and future, contractually agreed royalties.

Profitability is expected to benefit from greater contribution from scalable, higher-margin activities, operating leverage and continued cost efficiency.

Financial Results

Claire Hinshelwood, Chief Financial Officer of Evotec, said:

“Our strong third-quarter performance reflects the positive impact of the commercial investments and Horizon initiatives launched earlier this year. We are now seeing these efforts translate into improved profitability and operational momentum. Looking ahead, our focus remains on converting this momentum into sustainable revenue growth and stronger cash generation, while maintaining disciplined cost management, liquidity oversight, and capital allocation. Today, we are pleased to provide greater transparency into our 2030 financial framework, including the business mix and operational drivers that support a high-quality, diversified platform for future earnings growth.”

Group Financials

For the third quarter of 2026, Group revenue amounted to €164.9 million (€164.2 million CER), essentially unchanged from €163.9 million in the prior-year quarter. Adjusted Group EBITDA was -€1.6 million (-€1.7 million CER), versus -€15.0 million in the same prior‑year period, reflecting a marked year-on-year improvement of 89.1% primarily attributable to lower cost of revenue.

For the nine months ended September 30, 2026, Group revenue amounted to €465.0 million (€477.4 million CER), compared with €535.1 million in the prior-year period, reflecting a 13.1% decline. Consistent with the Company’s focus on cost discipline, R&D expenses amounted to €29.7 million or 6.4% of total Group revenue, compared with €42.3 million or 7.9% of total Group revenue in the prior-year period. Adjusted Group EBITDA decreased to
-€44.3 million (-€39.1 million CER), down from -€16.9 million for the nine months ending September 30, 2025. The decrease in revenue was partially offset by lower cost of revenue.

Evotec closed the third quarter of 2026 with a liquidity position of €400.9 million, reflecting a net debt position.

Segment Financials (excluding intersegment revenue)

Discovery and Preclinical Development (D&PD)

For the third quarter of 2026, revenue for Discovery & Preclinical Development totaled €120.1 million (€119.6 million CER), representing a modest year-on-year decline of 2.3%. Adjusted EBITDA for the quarter improved to
-€1.0 million (-€1.4 million CER), compared with -€9.5 million in the third quarter of 2025.

For the first nine months of 2026, revenue totaled €348.0 million (€355.5 million CER), compared with
€391.9 million in the prior-year period. The 11.2% year-on-year decrease was primarily driven by lower sales-to-revenue conversion across all D&PD segments. Adjusted EBITDA for the segment was -€25.5 million
(-€19.8 million CER), compared with -€18.8 million in the prior-year period. The decrease was primarily driven by lower revenue and partially offset by a lower cost base across cost of revenue, R&D and SG&A.

Just – Evotec Biologics (JEB)

Third quarter 2026 revenue at Just – Evotec Biologics totaled €44.8 million (€44.6 million CER), representing a 9.4% increase compared with the prior-year period. Adjusted EBITDA reached -€0.6 million (-€0.3 million CER), compared with -€5.5 million in the prior-year period.

For the first nine months of 2026, revenue totaled €117.1 million (€121.9 million CER), compared with
€143.2 million in the same period in 2025. The 18.3% year-on-year decrease was primarily driven by the $25 million Sandoz license sale recognized in Q1 2025 and delayed program activities. Adjusted EBITDA amounted to
-€18.8 million (-€19.3 million CER), compared with an Adjusted EBITDA of €1.9 million in the prior-year period.

Reaffirming Full-Year 2026 Guidance

Evotec confirms its full-year 2026 outlook for Group revenue of approximately €570 to €610 million (€595 to
€635 million CER) and adjusted Group EBITDA of approximately -€105 to -€70 million (-€90 to -€60 million CER).

Strategic Review

The strategic evaluation announced in connection with the Company’s first quarter 2026 results on May 6, 2026, remains ongoing and continues alongside the implementation of the Horizon transformation program. Additional details regarding the review are available in the Company’s Q1 2026 results announcement.

 
Webcast Details

Evotec will host a webcast and conference call today at 2 p.m. CET / 1 p.m. GMT / 8 a.m. EST.

To join the audio webcast and to access the presentation slides, please register via this link.

The on-demand replay of the webcast will be available under the same link after the event and on our website.

Conference Call Details

To join the conference call, please pre-register via this link. You will receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.
A simultaneous slide presentation for participants dialing in via phone is available under this link.

 
*Net Sales: includes signed work orders, positive change orders and negative change orders
 

About Evotec SE

Evotec is a life science company pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, Evotec accelerates the journey from concept to cure with greater speed, intelligence and precision. The company’s expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms including Molecular Patient Databases, PanOmics and induced pluripotent stem cell-based disease modeling. Through flexible partnering models tailored to customers’ needs, Evotec works with all Top 20 pharmaceutical companies, more than 800 biotechnology companies, academic institutions and other healthcare stakeholders. Evotec’s offerings range from standalone services to fully integrated research and development programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, the company is redefining biologics development and manufacturing to improve accessibility and affordability. With a portfolio of more than 100 proprietary research and development assets, most of which are co-owned, Evotec focuses on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology and immunology. Evotec’s global team of around 4,500 experts operates from sites in Europe and the United States, providing complementary technologies and services through a network of synergistic centers of excellence. Learn more at www.evotec.com and follow Evotec on LinkedIn and X at @Evotec.

 

Forward-Looking Statements

This announcement contains forward-looking statements concerning future events, including Evotec’s financial results, full-year 2026 outlook, expected commercial conversion, anticipated strategic partnership and milestone contributions, Horizon implementation, expected cost savings, liquidity, financial flexibility and future business performance. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of these words and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on information available to Evotec and on expectations and assumptions considered reasonable by the company at the time the statements were made. No assurance can be given that these expectations will prove correct. Forward-looking statements involve known and unknown risks and are based on assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond Evotec’s control. Evotec expressly disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement to reflect changes in expectations, events, conditions or circumstances, except as required by applicable law.

 

Investor Relations and Media Contact

Dr. Sarah Fakih
EVP, Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.com

 

Key figures of consolidated income statement & segment information
 

    Three months ended 30 September 2026   Three months ended 30 September 2025
(in € thousands)   D&PD JEB Evotec Group   D&PD JEB Evotec Group
Revenue   120,086 44,840 164,926   122,892 40,994 163,887
Intersegment revenue   81  __ __   166 103 __
Costs of revenue   (102,460) (42,752) (145,130)   (110,909) (46,495) (157,135)
Gross profit   17,708 2,088 19,796   12,150 (5,397) 6,752
Gross margin   14.7% 4.7% 12.0%   9.9% (13.1)% 4.1%
R&D expenses   (9,344) __ (9,344)   (12,839) (9) (12,848)
SG&A expenses   (30,659) (8,125) (38,784)   (38,036) (6,954) (44,990)
Other operating income   8,587 540 9,127   10,630 1,099 11,730
Other operating expense   (4,323) (3,586) (7,909)   (2,157) (3,097) (5,254)
Reorganization costs   7,003 __ 7,003   108 __ 108
Operating income (loss)   (11,029) (9,083) (20,112)   (30,145) (14,357) (44,502)
Adjusted EBITDA   (1,032) (600) (1,632)   (9,498) (5,538) (15,036)

 

    Nine months ended 30 September 2026   Nine months ended 30 September 2025
(in € thousands)   D&PD JEB Evotec Group   D&PD JEB Evotec Group
Revenue   347,955 117,094 465,049   391,861  143,239 535,100
Intersegment revenue   287 __ __   195 126 __
Costs of revenue   (320,426) (128,262) (448,402)   (338,876) (139,432) (477,987)
Gross profit   27,815 (11,168) 16,647   53,180 3,933 57,114
Gross margin in %   8.0% (9.5)% 3.6%   13.6% 2.7% 10.7%
R&D expenses   (29,682) __ (29,682)   (42,185) (71) (42,256)
SG&A expenses   (97,155) (24,707) (121,862)   (115,815) (22,585) (138,400)
Other operating income   29,553 1,603 31,156   38,516 2,856 41,371
Other operating expense   (53,987) (5,132) (59,119)   (7,224) (3,631) (10,855)
Reorganization costs   (91,922) __ (91,922)   741 __ 741
Operating income (loss)   (215,377) (39,405) (254,781)   (72,786) (19,499) (92,284)
Adjusted EBITDA   (25,470) (18,846) (44,316)   (18,826) 1,940 (16,886)

 


05.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Tradegate BSX; Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; Nasdaq
LEI Code: 529900F9KI6OYITO9B12
EQS News ID: 2428688

 
End of News EQS News Service

2428688  05.11.2026 CET/CEST

EvoNext Holdings SA makes available the consolidated financial statements of Ascend Sport Technology AG for the financial year 2025/26

EvoNext Holdings SA / Key word(s): Merger

EvoNext Holdings SA makes available the consolidated financial statements of Ascend Sport Technology AG for the financial year 2025/26

05-Nov-2026 / 07:10 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.


This press release or the information contained therein is not being issued and may not be distributed in the United States of America, Canada, Australia or Japan or any other jurisdiction in which the distribution or release would be unlawful or require registration or any other measure and does not constitute an offer of securities for sale in any country.

PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

EvoNext Holdings SA makes available the consolidated financial statements of Ascend Sport Technology AG for the financial year 2025/26

Reinach / Lucerne, Switzerland, 5 November 2026 – As part of the transaction documentation ahead of the upcoming merger, today EvoNext Holdings SA is making available the unaudited consolidated financial statements of Ascend Sport Technology AG (“Ascend”) for the financial year ended 30 June 2026, together with comparative figures for the financial year ended 30 June 2025.

Ascend reports the following unaudited key figures1:

In CHF million FY 2025/26   FY 2024/25
Income Statement
Net revenues 43.8 37.3
EBITDA 25.0 18.9
Depreciation (3.5) (3.2)
Amortization (9.4) (8.1)
EBIT 12.0 7.5
Net profit 8.7 5.3
Balance Sheet
Cash and cash equivalents   30.1 26.8
Securities 3.0 3.9
Net working capital2 15.1 8.9
Financial liabilities3 2.6 4.0
Total equity 76.0 66.8

1 Net revenues, EBITDA, depreciation, amortization, EBIT and net profit relate to the financial years from 1 July to 30 June (FY 2025/26 and FY 2024/25); all balance sheet items are stated as at 30 June 2026 and 30 June 2025, respectively.
2 Net working capital comprises trade receivables, other current receivables, inventories and accrued income and prepaid expenses, less trade payables, other current liabilities, current provisions and deferred revenue and accrued expenses. It excludes cash and cash equivalents, securities, financial liabilities and non-current provisions.
3 Financial liabilities comprise current and non-current financial liabilities (FY 2025/26: CHF 2.6 million current, nil non-current; FY 2024/25: CHF 2.1 million current, CHF 1.9 million non-current).

All figures are unaudited.

The complete unaudited consolidated financial statements of Ascend for the financial year 2025/26 (without notes), comprising the consolidated balance sheet, income statement and cash flow statement, are available here.

EvoNext Holdings SA and Ascend Sport Technology AG signed the merger agreement on 1 November 2026. The Swiss sports technology holding company Ascend is expected to become, subject to certain conditions including the approval of the shareholders of both companies, a publicly listed entity through a merger into EvoNext with its existing listing on SIX Swiss Exchange.

Contact for investors and media

EvoNext Holdings SA

investors@evonextholdings.com

susanne.muehlemann@lemongrass.agency / +41 79 223 70 81

Disclaimer

This publication constitutes neither an offer to sell nor a solicitation to buy securities of EvoNext Holdings SA and it does not constitute a prospectus or a similar notice within the meaning of articles 35 et seqq. or 69 of the Swiss Financial Services Act. Any offer and listing of any securities in EvoNext Holdings SA (“Securities”) will be made solely by means of, and on the basis of, a prospectus which is to be published. An investment decision regarding any publicly offered Securities should only be made on the basis of such prospectus. The prospectus will be available free of charge from the accompanying bank.

This publication may contain specific forward-looking statements, e.g., statements including terms like “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of EvoNext Holdings SA or Ascend Sport Technology AG and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. EvoNext Holdings SA assumes no responsibility to update forward-looking statements or to adapt them to future events or developments. Moreover, financial information contained in this publication may be preliminary and unaudited.

This communication is being distributed only to, and is directed only at (i) persons outside the United Kingdom, (ii) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth entities, and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as “Relevant Persons”). Any potential investment or investment activity to which this communication relates will be available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person who is not a Relevant Person must not act or rely on this communication or any of its contents.

This communication does not constitute an “offer of securities to the public” within the meaning of Regulation 2017/1129 of the European Union (the “Prospectus Regulation”) of the securities referred to in it (the “Securities”) in any member state of the European Economic Area (the “EEA”) or, in the United Kingdom (“UK”), the UK Public Offers and Admissions to Trading Regulations 2024 (the “POATRs”). Any placements of any Securities to persons in the EEA or the UK will be made pursuant to an exemption under the Prospectus Regulation or the POATRs (as applicable), as implemented in member states of the EEA or the UK, from the requirement to produce a prospectus for offers of Securities.

Any securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States or to US persons (as such term is defined in Regulation S under the Securities Act) unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. The issuer of the securities has not registered, and does not intend to register, any portion of any potential placements in the United States, and does not intend to conduct a public offer of securities in the United States.

This communication is not for distribution in the United States, Canada, Australia, Japan or any other jurisdiction into which the same would be unlawful and does not constitute an offer of securities for sale in such countries. This communication does not constitute an offer to sell, or the solicitation of an offer to buy, securities in any jurisdiction in which is unlawful to do so.

Additional features:

File: 2026_11_05_EvoNext Ad hoc PRESS RELEASE_Ascend Sport Technology consolidated financial statements FY 25_26


End of Inside Information


Language: English
Company: EvoNext Holdings SA
Angensteinerstrasse 6
4153 Reinach
Switzerland
Phone: +41 61 485 20 00
E-mail: investors@evonextholdings.com
Internet: www.evonextholdings.com
ISIN: CH1262055788
Valor: 126205578
Listed: SIX Swiss Exchange
EQS News ID: 2428734

 
End of Announcement EQS News Service

2428734  05-Nov-2026 CET/CEST

PolyPeptide Group: Definitive end result of the public tender offer of Samsung Biologics Co., Ltd.

PolyPeptide Group / Key word(s): Tender Offer

PolyPeptide Group: Definitive end result of the public tender offer of Samsung Biologics Co., Ltd.

05-Nov-2026 / 07:05 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.


Media Release – ad hoc announcement pursuant to Art. 53 LR

 

Definitive end result of the public tender offer of Samsung Biologics Co., Ltd.

Baar, Switzerland, 5 November 2026 – Samsung Biologics Co., Ltd. (“Samsung Biologics”), through its direct subsidiary Samsung Peptide AG (“Samsung Peptide”), today published the definitive end result of its public tender offer (the “Offer”) for all publicly held registered shares of PolyPeptide Group AG (“PolyPeptide”) (SIX: PPGN).

The additional acceptance period of the Offer ended on 30 October 2026, at 4:00 p.m. Swiss time. According to the definitive end result as published by Samsung Peptide,

  • the participation of Samsung Peptide and the persons acting in concert with Samsung Peptide amounts to 32,458,892 PolyPeptide shares in aggregate, corresponding to 97.99% of the issued share capital and voting rights of PolyPeptide (participation rate); and
  • 32,350,302 PolyPeptide shares were tendered into the Offer until the end of the additional acceptance period of the Offer, corresponding to 97.66% of the issued share capital and voting rights of PolyPeptide and 97.98% of all PolyPeptide shares to which the Offer relates (success rate).

The definitive end result that has been published today by Samsung Peptide is available at https://samsungbiologics.com/offer.

According to the definitive end result as published by Samsung Peptide, the Offer remains subject to certain remaining Offer conditions, including the receipt of regulatory approvals in certain jurisdictions.

In its provisional end result published on 2 November 2026, Samsung postponed the settlement of the Offer in accordance with section B.7.3 (Period for which the Offer Conditions are in Force and Effect and Deferral) of the offer prospectus of Samsung Peptide dated 31 August 2026 (the “Offer Prospectus”). Samsung confirmed in its provisional and definitive end result that based on the current understanding of the regulatory approval procedures in various countries (see the Offer condition pursuant to section B.7.1(b) (Merger and FDI Clearances) of the Offer Prospectus), the transaction is currently expected to be completed towards the end of 2026 or in Q1 2027.

According to the definitive end result as published by Samsung Peptide, Samsung Peptide intends to pursue a squeeze-out of any remaining public shareholders and to apply to SIX Exchange Regulation for the delisting of the PolyPeptide shares following the settlement of the Offer.

 

Contact

PolyPeptide Group AG
Strategic Marketing and Corporate Communications
Laura Rosso
mediateam@polypeptide.com
T: +41 43 502 0580

PolyPeptide Group AG
Finance / Investor Relations
Tim Brandl
investorrelations@polypeptide.com
T: +41 43 502 0580 

 

About PolyPeptide

PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-pre-clinical to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with significant exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit polypeptide.com.

@PolyPeptide — follow us on LinkedIn

About Samsung Peptide and Samsung Biologics

Samsung Peptide is a direct subsidiary of Samsung Biologics. Samsung Biologics and PolyPeptide have concluded a transaction agreement on 17 July 2026 regarding the Offer. Samsung Peptide is acting as the formal offeror of the Offer. Samsung Biologics (KRX: 207940.KS) is a leading Contract Development & Manufacturing Organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing. With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II in Korea, and 60,000 from the manufacturing facility in Rockville, Maryland, U.S., Samsung Biologics holds total global manufacturing capacity of 845,000 liters. Samsung Biologics has also secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities. Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity. Samsung Biologics’ global manufacturing and commercial network spans Korea, the U.S., Europe, and Japan. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. Samsung Biologics is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health. For more information, please visit https://samsungbiologics.com.

Legal Notice and Disclaimer

No Offer / Offer Restrictions

The information in this media release is for informational purposes only. It does not constitute, or form part of, any offer or invitation to purchase, sell, exchange or issue, or any solicitation of an offer to sell, purchase, exchange or subscribe to, any registered shares or other securities of PolyPeptide or any other person, nor shall it form the basis of, or be relied upon in connection with, any contract in relation thereto. This media release is not part of Samsung Peptide’s publication of the definitive end result of the Offer or any other publication, communication or other documentation of Samsung Peptide or Samsung Biologics relating to the Offer, including without limitation the Offer Prospectus (the “Offer Documentation”). Terms and conditions of the Offer have been published by Samsung Peptide and Samsung Biologics in the Offer Documentation. Shareholders of PolyPeptide are urged to read the Offer Documentation, which is available at https://samsungbiologics.com/offer.

This announcement is not for publication, release or distribution in any country or jurisdiction in which it would be considered unlawful or otherwise violate any applicable laws or regulations, or which would require Samsung Peptide or Samsung Biologics to change or amend the terms or conditions of the Offer in any way, to make an additional filing with any governmental, regulatory or other authority or take additional action in relation to the Offer. Full Offer restrictions can be found in Samsung Peptide’s Offer Prospectus at https://samsungbiologics.com/offer.

Forward-looking Information and Statements

This media release has been prepared by PolyPeptide and includes forward-looking information and statements concerning the outlook for the Group’s business. These statements are based on current expectations, estimates and projections about the factors that may affect the Group’s future performance. These expectations, estimates and projections are generally identifiable by statements containing words such as ‘expects’, ‘believes’, ‘estimates’, ‘targets’, ‘plans’, ‘projects’, ‘outlook’ or similar expressions. There are numerous risks, uncertainties and other factors, many of which are beyond PolyPeptide’s control, that could cause the group’s actual results to differ materially from the forward-looking information and statements made in this media release and that could affect the group’s ability to achieve its stated targets. Although PolyPeptide believes that its expectations reflected in any such forward-looking statement are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved.

Except as otherwise required by law, PolyPeptide disclaims any intention or obligation to update any forward-looking statements as a result of developments.

 

Additional features:

File: 20261105_PolyPeptide_Media_Release_Tender_Offer


End of Inside Information


Language: English
Company: PolyPeptide Group
Neuhofstrasse 24
6340 Baar
Switzerland
Phone: +41435020580
E-mail: mediateam@polypeptide.com
Internet: www.polypeptide.com
ISIN: CH1110760852
Valor: 111076085
Listed: SIX Swiss Exchange
EQS News ID: 2428776

 
End of Announcement EQS News Service

2428776  05-Nov-2026 CET/CEST

Topadur’s Phase 2a Trial of TOP-N53 for Systemic Sclerosis-Associated Digital Ulcers Advances to Next Dose Levels

Topadur Pharma AG

/ Key word(s): Study

Topadur’s Phase 2a Trial of TOP-N53 for Systemic Sclerosis-Associated Digital Ulcers Advances to Next Dose Levels

05.11.2026 / 07:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


Topadur’s Phase 2a Trial of TOP-N53 for Systemic Sclerosis-Associated Digital Ulcers Advances to Next Dose Levels

Schlieren-Zurich, Switzerland, 05 November 2026 – Topadur Pharma AG, a Swiss clinical-stage biopharmaceutical company, today announced that the Safety Review Committee of its Phase 2a trial has recommended progression to the next planned dose levels. The trial is evaluating lead candidate TOP-N53 for the treatment of systemic sclerosis-associated digital ulcers. The recommendation follows a review of safety data and the completion of the first patient cohort. No protocol-defined stopping criteria were met, and no serious adverse drug reactions were reported.

TOP-N53 is a novel, bifunctional topical therapeutic candidate designed to improve microcirculation and support tissue repair. By combining nitric oxide (NO) release and phosphodiesterase-5 (PDE5) inhibition in a single small molecule, TOP-N53 aims to enhance cGMP signaling directly at the site of application. Its clinical development builds on a first-in-human Phase 1 study in healthy volunteers, which demonstrated favorable tolerability and increased local skin perfusion following subcutaneous administration. TOP-N53 holds orphan drug designation in both the US and the European Union for the treatment of systemic sclerosis-associated digital ulcers. The ongoing open-label, vehicle-controlled Phase 2a trial (NCT06954597), conducted in Switzerland and France, evaluates the safety and tolerability of ascending doses of TOP-N53 applied topically to digital ulcers in patients with systemic sclerosis.

“TOP-N53 is a key program for Topadur as we investigate the potential of locally acting therapies to address diseases with significant unmet medical needs,” said PD Dr. Matthias Schäfer, CEO of Topadur Pharma AG. “With the Safety Review Committee’s recommendation to proceed to the next dose levels, we have reached an important milestone in the clinical development of TOP-N53. We are grateful to the patients and clinical teams whose participation and dedication make it possible to move this clinical trial forward.”

Systemic sclerosis is a rare autoimmune disease characterized by damage to small blood vessels and fibrosis of the skin and internal organs. About half of patients develop digital ulcers, painful wounds on the fingers that are often slow to heal and prone to recurrence. Treatment options for existing ulcers remain limited, and current drug treatments act systemically. A 2025 consensus report by the World Scleroderma Foundation[i] highlights the significant unmet medical need for local treatment strategies for digital ulcers.

“Even a single digital ulcer can cause significant pain and severely affect a patient’s daily life, making activities as simple as buttoning a shirt or holding a pen difficult,” said Prof. Marie-Elise Truchetet, Department of Rheumatology, CHU de Bordeaux, France, and Principal Investigator at the Bordeaux study site. “There is a clear need for new local treatment options. Evaluating the safety and tolerability of TOP-N53 at increasing doses is an important step towards understanding its potential for patients with digital ulcers.”

The trial is part of a start-up innovation project supported by Innosuisse. Recruitment for the second cohort is scheduled to begin in November at six clinical centers in Switzerland and France, coinciding with the colder months, when new digital ulcers occur more frequently.

About Topadur Pharma AG
Topadur Pharma AG, based in Schlieren-Zurich, Switzerland, is a clinical-stage biopharmaceutical company developing locally acting small-molecule therapies. Its proprietary DualTOP® platform targets the cGMP signaling pathway, a central regulator of vascular regeneration and tissue repair. Building on this technology, the company is advancing a pipeline of therapeutic candidates for age- and disease-related conditions with significant unmet medical needs. Topadur’s lead candidate, TOP-N53, is undergoing Phase 2a clinical evaluation for the treatment of digital ulcers in patients with systemic sclerosis. In parallel, TOP-M119 is being prepared for first-in-human clinical trials targeting alopecia. For more information, please visit www.topadur.com and follow us on LinkedIn.

Contacts

Topadur Pharma AG
Yoshita Bhide
Media Communications
+41 44 755 44 66
yoshita.bhide@topadur.com

Media inquiries:
MC Services

Anne Hennecke, Julia Bittner
+49 89 210 2280
contact@mc-services.eu
 

Disclaimer

TOP-N53 is an investigational product and has not been approved by Swissmedic, the European Commission, the US Food and Drug Administration or any other regulatory authority. Its safety and efficacy have not been established. Observations from the first cohort are preliminary, based on a small number of patients treated at the lowest dose in an open-label setting, and may not predict results at higher doses or of the completed trial. This press release is intended for media and investors; it does not promote any medicinal product, provide medical advice or invite participation in a clinical trial.

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Topadur Pharma AG. This publication contains forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.

 

[i] Campochiaro C, et al. “Recommendations for the local management of digital ulcers in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) ‘Ad hoc committee’.” J Scleroderma Relat Disord 2025;10(3):276–284. https://doi.org/10.1177/23971983251339821


05.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


2428542  05.11.2026 CET/CEST

AEVIS VICTORIA SA: Continued Revenue Growth in the Third Quarter of 2026

AEVIS VICTORIA SA / Key word(s): 9 Month figures

AEVIS VICTORIA SA: Continued Revenue Growth in the Third Quarter of 2026

05-Nov-2026 / 07:00 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.


Ad hoc announcement pursuant to Art. 53 LR

Fribourg, 5 November 2026

AEVIS VICTORIA SA: Continued Revenue Growth in the Third Quarter of 2026

Consolidated gross revenue up 8.2% (7.7% organic), driven by healthcare. Net revenue stable at CHF 789.4 million, up 0.6% on a like-for-like basis.

In the first nine months of 2026, AEVIS VICTORIA SA generated consolidated gross revenue of CHF 972.7 million (9M 2025: CHF 899.2 million), an increase of 8.2%. Net revenue, the Group’s key reference metric, amounted to CHF 789.4 million (9M 2025: CHF 789.9 million), stable (-0.1%). Excluding scope effects and the sale of apartments in Zermatt recognized in 2025, net revenue grew by 0.6%.

The growth in gross revenue mainly reflects the presentation of fees of independent physicians at Swiss Medical Network. These fees are recognized in gross revenue and then passed through as third-party services; they amounted to CHF 183.3 million (9M 2025: CHF 109.3 million). Net revenue, which excludes these fees, is the Group’s key reference metric.

Healthcare: Solid Growth and Integration of Radiologia Ticino
Swiss Medical Network, which operates 18 clinics and hospitals and 80 outpatient centers, generated gross revenue of CHF 804.2 million (9M 2025: CHF 722.6 million), up 11.3% (10.7% organic). Net revenue rose 1.2% to CHF 620.9 million (9M 2025: CHF 613.3 million). On a constant scope basis, i.e., excluding Radiologia Ticino, which has been consolidated since January 1, 2026, growth was 0.5%, or 1.6% excluding the impact of the restructuring of Privatklinik Lindberg.

The hospital business posted gross revenue of CHF 632.9 million (+12.2%) and net revenue of CHF 466.3 million, a slight decrease of 0.5% (+0.8% excluding Privatklinik Lindberg). The outpatient business recorded gross revenue of CHF 91.6 million (+6.2%) and net revenue of CHF 80.0 million (+5.2%), of which CHF 4.4 million was contributed by Radiologia Ticino.

The transfer of Privatklinik Lindberg’s medical activities to the Bethanien (Zurich) and Belair (Schaffhausen) clinics has been completed; Kantonsspital Winterthur took over the premises on October 1, 2026. The full positive impact of this measure will be felt from fiscal year 2027. The continuous improvement in profitability over the first nine months, combined with the restructuring measures implemented, provides a solid foundation for the remainder of fiscal year 2026 and for 2027.

Hospitality: Higher Average Rates and Acceleration at Period-End
MRH Switzerland AG, the Group’s hospitality division managed by Michel Reybier Hospitality, generated revenue of CHF 159.5 million (9M 2025: CHF 157.4 million), up 1.3%, entirely organic. The average daily rate rose 5.4% to CHF 607 and revenue per available room (RevPAR) 5.1% to CHF 348, with occupancy virtually stable at 57.4%. Momentum picked up significantly toward the end of the period, with September revenue up 9.2%.

Real Estate: Rental Income Up 12.2%
Swiss Hotel Properties SA generated revenue of CHF 29.5 million (9M 2025: CHF 36.1 million). The decline reflects the comparison base, which included CHF 10.1 million in gains on the sale of apartments in Zermatt (CHF 0.3 million in 2026). Rental income rose 12.2% to CHF 29.2 million.

For further information
Media and Investor Relations: c/o Dynamics Group, Zurich
Marion Schihin, msc@dynamicsgroup.ch, +41 79 705 88 15

AEVIS VICTORIA SA – Investing for a better life
AEVIS VICTORIA SA invests in healthcare, hospitality & lifestyle and infrastructure. AEVIS’s main shareholdings are Swiss Medical Network Holding SA (76.3%, directly and indirectly), the only Swiss private network of hospitals present in the country’s three main language regions, MRH Switzerland AG, a luxury hotel group managing eleven hotels in Switzerland and abroad, Infracore SA (22.6%, directly and indirectly), a listed real estate company (INFRAC.SW) dedicated to healthcare-related infrastructure, Swiss Hotel Properties SA, a hospitality real estate division, and NESCENS SA, a brand dedicated to better aging. AEVIS is listed on the Swiss Reporting Standard of the SIX Swiss Exchange (AEVS.SW). www.aevis.com.


End of Inside Information


2428694  05-Nov-2026 CET/CEST

Iksuda to Present First Clinical Data for IKS03 in Advanced B-Cell Non-Hodgkin Lymphomas at ASH

Iksuda to Present First Clinical Data for IKS03 in Advanced B-Cell Non-Hodgkin Lymphomas at ASH




Iksuda to Present First Clinical Data for IKS03 in Advanced B-Cell Non-Hodgkin Lymphomas at ASH

Impressive early anti-tumour activity and a therapy-leading safety profile seen in heavily pretreated patients across multiple B-cell lymphoma subtypes

Objective response rate of 53% in 17 efficacy evaluable patients, including responses in patients previously treated with CD19-directed CAR-T cell therapy

NEWCASTLE, England–(BUSINESS WIRE)–Iksuda Therapeutics (Iksuda), the developer of class leading, antibody drug conjugates (ADCs), today announces the presentation of preliminary data from the dose escalation portion of its Phase 1 study of IKS03, a CD19-directed ADC, in patients with advanced B-cell non-Hodgkin lymphoma (B-NHL), at the 68th American Society of Hematology (ASH) Annual Meeting, December 12–15, 2026, New Orleans, Louisiana.

As of 8 July 2026, 21 patients (median age 67 years) with a median of four prior lines of therapy (range 2-8) have been treated with IKS03 across five dose levels up to 3.1 mg/m2 (approximately 84µg/kg). A maximum tolerated dose (MTD) has not been reached.

IKS03 showed a highly differentiated and manageable safety profile, with treatment-related adverse events (TRAEs) affecting only seven of 21 patients. Compared with other treatments across modalities, there was a markedly lower frequency of high-grade neutropenia and thrombocytopenia and an absence of peripheral neuropathy. A single Grade 4 neutropenia (4.8%), a dose-limiting toxicity, was observed in the fourth dose cohort in a patient with follicular lymphoma and bone marrow involvement, and who had previously received six prior regimens including CAR-T. On resolution, the patient remained on therapy and in response. There were only two Grade 3 neutropenia events, and all remaining TRAEs were mild or moderate (Grade 1–2). No patient experienced a Grade 5 event or a treatment-related serious adverse event, and none stopped treatment because of an adverse event. Non-haematological toxicity was both limited and low-grade.

Responses to treatment were observed from the lowest dose level (around 20 µg/kg) and across all dose cohorts. Of 17 patients evaluable for efficacy (those who had completed two treatment cycles across the first four dose levels), nine responded, giving an overall objective response rate (ORR) of 53%, with two patients achieving stable disease. Five patients (29%) achieved a complete metabolic response: two with follicular lymphoma and one each with diffuse large B-cell lymphoma, marginal zone lymphoma and T cell/histiocyte-rich large B-cell lymphoma. Four patients (24%) achieved a partial metabolic response, two each with follicular lymphoma and marginal zone lymphoma.

Responses were seen in patients who were CAR-T naïve, as well as in those who had received prior CAR-T (3 of 4 patients), including a durable complete response in a patient who had received 8 prior regimens which included failed responses to CAR-T and allogeneic transplantation. Of the eight patients who did not respond, five were being treated for Richter-transformed diffuse large B-cell lymphoma, well known to be highly aggressive and difficult to treat.

Responses have lasted up to 14 months. Currently, six of the nine responders eligible for efficacy assessment at the time of writing remain on treatment. Dose escalation is ongoing and updated results will be presented at the convention.

Dr. Dave Simpson, Chief Executive Officer, Iksuda Therapeutics, commented: “These first clinical data for IKS03 are incredibly exciting. To see responses in patients treated from the lowest dose level and across all cohorts, in heavily pretreated patients including those who had previously received CD19-directed CAR-T therapy, is immensely rewarding, whilst the safety profile is distinct from all other therapies in use for these cancers. These results support the design strategy of tumour-selective payload release, and we look forward to onward progression of this exciting program.”

Prof. Enrico Derenzini, European Institute of Oncology IRCCS, Milan, added: “Patients with relapsed or refractory B-cell lymphoma who have already received several lines of treatment have limited options. To see responses at this early stage, alongside a manageable safety profile, is encouraging and supports further evaluation of IKS03.”

The Phase 1 study (NCT05365659) is a first-in-human, multicentre trial of IKS03 in patients with relapsed or refractory B-NHL who have received at least two prior systemic therapies. Part I (dose escalation) uses a 3+3 design to determine the MTD and recommended Phase 2 dose in patients with CD19-positive follicular, marginal zone, mantle cell, large B-cell (including Richter-transformed) or high-grade B-cell lymphoma. Part II will assess efficacy in disease-specific expansion cohorts. Around 140 patients are expected to be enrolled across the study.

Presentation details

Abstract number: 5456

Title: First-in-human phase 1 trial to determine safety and preliminary antineoplastic activity of IKS03, a CD19-targeting PBD prodrug antibody drug conjugate, in advanced B-cell non-Hodgkin lymphomas

Presenter: Prof. Enrico Derenzini

Session Name: 629. Aggressive Lymphomas, Non-Cellular Immunotherapy including Bispecific Antibodies: Poster III

Session Date: December 14, 2026

Session Time: 12/14/2026 6:00:00 PM – 12/14/2026 8:00:00 PM

Presentation Time: 12/14/2026 6:00:00 PM – 12/14/2026 8:00:00 PM

Room: MCCNO – Hall F

About IKS03

IKS03 is a best-in-class CD19-targeting ADC delivering a tumour-activated prodrug pyrrolobenzodiazepine (PBD) which was licensed from LigaChem Biosciences (formerly LegoChem Biosciences). Preclinical testing demonstrated best-in-class efficacy (vs in-clinic and marketed CD19-targeted therapies) in in vivo xenograft models and significantly raised maximum tolerated dose (MTD) in non-human primate disease models, demonstrating its potential to be the leading anti-CD19 therapy in B-cell cancers.

About Iksuda Therapeutics: www.iksuda.com

Iksuda Therapeutics is a clinical stage, UK-based biotechnology company focussed on the development of class leading ADCs targeting difficult-to-treat haematological and solid tumours. Iksuda’s pipeline of ADCs is centred on a portfolio of prodrug ADCs which utilise tumour-selective release and activation of payloads, incorporating proprietary and in-licensed (from LigaChem Biosciences) prodrug and linker technologies in combination with stable conjugation chemistries including its proprietary PermaLink® platform. The early pipeline incorporates Iksuda’s proprietary, first-in-class protein alkylating payload class, ‘ProAlk™. The Company’s design concepts for ADCs are now clinically validated to significantly improve the therapeutic index of this important modality and improve the outcomes for patients living with cancer.

Contacts

Iksuda Therapeutics
Dave Simpson, Chief Executive Officer

Tel: +44 (0) 191 6031680

info@iksuda.com

FTI Consulting (Financial Media and IR)

Simon Conway / Natalie Garland Collins / Amy Byrne

Tel: +44 (0) 020 3727 1000

Iksuda@fticonsulting.com

Innate Pharma Reports Third Quarter 2026 Business and Financial Update

Innate Pharma Reports Third Quarter 2026 Business and Financial Update




Innate Pharma Reports Third Quarter 2026 Business and Financial Update

  • Phase 1 dose-escalation data for Nectin-4 ADC IPH4502 to be presented at ENA 2026 on November 18, followed by a webcast and in-person event
  • Lacutamab, partnered with Sobi, progressing toward first patient dosing in the Phase 3 TELLOMAK-3 trial in Q1 2027, with an FDA accelerated approval filing planned in Sézary syndrome in H2 2027
  • AstraZeneca-led PACIFIC-9 Phase 3 trial of durvalumab in combination with monalizumab or oleclumab in unresectable Stage III NSCLC, readout expected in the first half of 2027
  • Cash position of €96.8 million1 as of September 30, 2026; anticipated cash horizon until the end of Q1 2028
  • Conference call to be held today at 2:00 p.m. CET / 8:00 a.m. ET

MARSEILLE, France–(BUSINESS WIRE)–$IPH #ADC–Regulatory News:


Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its financial update for the nine months ended September 30, 2026.

“As we approach year-end, our strengthened cash position enables us to work towards executing the next steps in advancing our strategic priorities,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “We look forward to presenting Phase 1 dose-escalation data from IPH4502, our differentiated Nectin-4 ADC, on November 18, while actively preparing for first patient dosing in the Phase 3 TELLOMAK-3 study of lacutamab in Q1 2027. We also look forward to the readout of the AstraZeneca-led PACIFIC-9 Phase 3 trial, which includes monalizumab and is now expected in the first half of 2027.”

________________

1 Including short term investments (€20.6m) and non-current financial instruments (€6.0m).

 

Webcast and conference call will be held today at 2:00pm CET (8:00am ET)

Access to live webcast:

Click here

 

Participants may also join via telephone using the registration link below:

Click here

 

This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com.

A replay of the webcast will be available on the Company website for 90 days following the event.

 

 

Pipeline highlights

IPH4502 (Nectin-4 exatecan ADC):

  • IPH4502 is Innate Pharma’s proprietary Nectin-4-targeting ADC, combining a differentiated antibody, a proprietary stable linker and an exatecan payload, with the potential to overcome Enfortumab Vedotin (EV) resistance in urothelial carcinoma (UC) and target tumors with low or heterogeneous Nectin-4 expression beyond UC. IPH4502 is currently being evaluated in a Phase 1 trial in advanced solid tumors known to express Nectin-4 (IPH4502-101; NCT06781983).
  • As announced in July 2026 (Link PR), enrollment in the Phase 1 dose-escalation of the IPH4502-101 study is complete, with 76 patients enrolled across multiple solid tumor types.
  • Phase 1 dose-escalation data will be presented as a poster at the 38th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, on November 18, 2026 (Barcelona).
  • Following the ENA presentation, Innate Pharma will host a hybrid event focused on IPH4502 on November 18, 2026, at 4:00 pm GMT (11:00 am ET) with in-person attendance in London at the IET London, Savoy Place and a live webcast accessible here.

Lacutamab (anti-KIR3DL2 antibody), developed in collaboration with Sobi:

  • As announced on August 10, 2026 (Link PR), Innate Pharma entered a strategic partnership with Sobi to license lacutamab in T-cell lymphoma.
  • Following closing of the transaction, Innate is advancing TELLOMAK-3, the confirmatory Phase 3 study of lacutamab in Cutaneous T Cell Lymphoma (CTCL), with first patient dosing expected in Q1 2027.
  • Phase 3 TELLOMAK-3 includes a confirmatory cohort in Sézary syndrome and a registrational cohort in Mycosis Fungoides.
  • Innate plans an FDA filing in H2 2027 for accelerated approval in Sézary syndrome based on the existing Phase 2 TELLOMAK data once the confirmatory Phase 3 study is underway (Link PR).

Monalizumab (anti-NKG2A antibody), developed in collaboration with AstraZeneca:

  • Enrollment is complete in the AstraZeneca-sponsored Phase 3 PACIFIC-9 study evaluating durvalumab in combination with monalizumab or oleclumab in patients with unresectable Stage III NSCLC who have not progressed following platinum-based chemoradiation therapy.
  • As announced on October 27 (Link PR), AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously. The revised timing reflects the event-driven nature of the study.

Corporate update

  • Frédéric Lombard, Chief Financial Officer, will step down from his position on December 31, 2026, to pursue new career opportunities. The Company thanks him for his contributions and dedication during his time with the Company. The Company has initiated a search of potential candidates to replace Mr. Lombard.
  • As of September 30, 2026, the balance available under our April 2023 sales agreement under the At-The-Market program remains at $75 million.

Financial highlights for Q3 2026

Cash, cash equivalents and financial assets of the Company amounted to €96.8 million as of September 30, 2026, which includes the $75 million upfront payment resulting from the closing of the Sobi transaction and the aggregate gross proceeds from the €30 million private placement offering of ordinary shares that occurred in August 2026. Also as of September 30, 2026, financial liabilities amounted to €16.2 million.

Revenues for the first nine months of 2026 amounted to €3.4 million (€2.3 million for the same period in 2025). Revenue from collaboration and licensing agreements mainly results from the partial or entire recognition of the proceeds received pursuant to the co-development and license agreements with AstraZeneca and research collaboration and license agreements with Sanofi.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise in antibody engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.

Innate Pharma is advancing a portfolio of differentiated potential first- and/or best-in-class assets, focused on areas of high unmet medical need. Its proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors, and supported by a preclinical portfolio of next-generation ADC candidates. In parallel, Innate is advancing two partnered late-stage assets: lacutamab, developed with Sobi for T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC).

Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sobi, Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.

Headquartered in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

ISIN code

Ticker code

LEI

FR0010331421

Euronext: IPH Nasdaq: IPHA

9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

For a discussion of risks and uncertainties, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

Contacts

Stéphanie Cornen

VP, Investor Relations & Corporate Communications

stephanie.cornen@innate-pharma.fr

Investor Relations

investors@innate-pharma.fr

Media

communication@innate-pharma.fr